Clinical Trials – Proof of Concept

CRST is a clinical research organisation specialising in proof of concept in phase I-II clinical trials that employ imaging and other biomarkers as surrogate endpoints.

Our Proof of concept studies showcases the most significant preclinical and clinical information to give you the best understanding of your test compound.

For drug development projects to advance proof of concept is required. We offer proof of concept in the crucial areas of safety, efficacy, and commercial and regulatory issues. CRST can offer a broad range of scientifically sound clinical, bio-analytical and preclinical research services that are tailored to your clinical development programmes.

The state of the art Turku PET Centre provides access to the latest developments in preclinical and clinical imaging technology.

Due to our expertise and availability of excellent resources CRST offer an efficient and comprehensive service.

What we offer:
• PET Imaging – provides a unique approach to obtain important clinical information on pharmacokinetics and pharmacodynamics, especially in therapy areas such as CNS, oncologic and metabolic disorders.
• Variety of test candidates – access to different patient populations and a large pool of healthy volunteers, allowing efficient subject recruitment.
• New Biomarkers – development and validation of new biomarkers as surrogate clinical safety and efficacy endpoints.

CRST has a dedicated team of clinical trials professionals to meet your needs:
• Clinical researchers
• Project managers
• Medical writers
• Study nurses, study monitors
• Laboratory technicians
• Research personnel

CRST and Turku PET Centre have provided imaging services for proof of concept in:
• CNS drug development
• Cancer drug development
• Metabolic and cardiovascular drug development

For more information or to discuss clinical trials – proof of concept please contact us directly.